Impact of axitinib therapy management on adverse event (AE) resolution/improvement (Res/Imp) among advanced renal cell carcinoma (aRCC) patients (Pts) receiving first-line (1L) axitinib plus checkpoint inhibitor (CPI) therapy

被引：0
|
作者：
Huynh, L. [1 ]
Du, S. S. [2 ]
Chang, R. [1 ]
Pi, S. [2 ]
Sundaresan, S. [1 ]
Duh, M. S. [1 ]
Thomaidou, D. [3 ]
Zanotti, G. [4 ]
Zakharia, Y. [5 ]
机构：
[1] Anal Grp Inc, Hlth Econ & Outcomes Res, Boston, MA USA
[2] Anal Grp Inc, Hlth Econ & Outcomes Res, New York, NY USA
[3] Pfizer Hellas, Global Med Affairs, Athens, Greece
[4] Pfizer Inc, Oncol HEOR, New York, NY USA
[5] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.093
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
75P
引用
收藏
页码：S1404 / S1405
页数：2
相关论文
共 50 条
  • [1] Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib plus Checkpoint Inhibitor
    Zakharia, Yousef
    Huynh, Lynn
    Du, Shawn
    Chang, Rose
    Pi, Selina
    Sundaresan, Sanjana
    Duh, Mei S.
    Zanotti, Giovanni
    Thomaidou, Despina
    CLINICAL GENITOURINARY CANCER, 2023, 21 (05) : E343 - E351
  • [2] Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
    Moshe C. Ornstein
    Laura S. Wood
    Advances in Therapy, 2023, 40 : 3599 - 3609
  • [3] Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
    Ornstein, Moshe C.
    Wood, Laura S.
    ADVANCES IN THERAPY, 2023, 40 (09) : 3599 - 3609
  • [4] Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
    Moshe C. Ornstein
    Laura S. Wood
    Advances in Therapy, 2023, 40 : 4116 - 4116
  • [5] First-line avelumab plus axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.
    Choueiri, Toni K.
    Larkin, James M. G.
    Oya, Mototsugu
    Thistlethwaite, Fiona C.
    Martignoni, Marcella
    Nathan, Paul D.
    Powles, Thomas
    McDermott, David F.
    Robbins, Paul B.
    Chism, David D.
    Cho, Daniel C.
    Atkins, Michael B.
    Gordon, Michael S.
    Gupta, Sumati
    Uemura, Hirotsugu
    Tomita, Yoshihiko
    Compagnoni, Anna
    Di Pietro, Alessandra
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma
    Zhu, Jiaxin
    Zhang, Tiantian
    Wan, Ning
    Liang, Zhuoru
    Li, Jiahao
    Chen, Xudong
    Liang, Wenhua
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (17) : 1237 - 1246
  • [7] The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell Carcinoma
    Parreira, Sara
    Burns, Kathleen
    Moldawer, Nancy
    Zomordian, Nazy
    Bandali, Nesan
    Virdee, Kiran
    Walsh, Meghara
    Kelly, Daniel
    Rao, Dharanija
    Teresi, Rosemary
    Wood, Laura S.
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [8] HEALTH STATE UTILITIES IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE PEMBROLIZUMAB PLUS AXITINIB OR SUNITINIB
    Bensimon, A.
    Lai, Y.
    Xu, R.
    Bhattacharya, R.
    Shinde, R.
    VALUE IN HEALTH, 2022, 25 (07) : S554 - S554
  • [9] Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
    Zakharia, Yousef
    Thomaidou, Despina
    Li, Benjamin
    Siu, Gordon
    Levin, Rebecca
    Vlahiotis, Anna
    Rao, Dharanija
    Zanotti, Giovanni
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Prognostic factors for patients with advanced renal cell carcinoma (aRCC) in the era of first-line (1L) treatment with immune checkpoint inhibitors (ICIs).
    Mantia, Charlene
    Jegede, Opeyemi
    Regan, Meredith M.
    Atkins, Michael B.
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345